Exelixis Adds Insilico Deal In Search Of Growth Beyond Cabometyx

After feeling the heat from activist investor Farallon Capital Management earlier this year, CEO Michael Morrissey has defended its spending on in-house R&D and in-licensing as it announced a new oncology deal.